RIPK3 Polyclonal Antibody, PE-Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-3551R-PE-Cy7 |
| Product Name | RIPK3 Polyclonal Antibody, PE-Cy7 Conjugated |
| Applications |
WB
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | PE-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human RIPK3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 11035 |
| Synonyms | Receptor interacting protein 3; Receptor interacting serine threonine kinase 3; Receptor interacting serine/threonine protein kinase 3; Receptor-interacting protein 3; Receptor-interacting serine/threonine-protein kinase 3; RIP 3; RIP like protein kinase 3; RIP-3; RIP-like protein kinase 3; RIPK 3; RIPK3; RIPK3_HUMAN. |
| Background | Certain serine/threonine protein kinases, such as ASK1, RIP, DAP, and ZIP kinases, are mediators of apoptosis. Receptor interacting proteins including RIP and RIP2/RICK mediate apoptosis induced by TNFR1 and Fas, two prototype members in the death receptor family. A novel member in the RIP kinase family was recently identified and designated RIP3. RIP3 contains an N terminal kinase domain but, unlike RIP or RIP2, lacks the C-terminal death or CARD domain. RIP3 binds to RIP and TNFR1, mediates TNFR1 induced apoptosis, and attenuates RIP and TNFR1 induced NF-kB activation. Over expression of RIP3 induces apoptosis and NF-kB activation. The messenger RNA of RIP3 is expressed in a subset of adult tissues. |
| Application Dilution | |
| WB | |